fluorodeoxyglucose f18 has been researched along with Carcinoma, Ductal, Pancreatic in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (15.38) | 29.6817 |
| 2010's | 35 (53.85) | 24.3611 |
| 2020's | 20 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Gai, Y; Kang, R; Li, H; Li, J; Li, Z; Muschler, J; Sun, L; Tang, D; Zeng, D | 1 |
| Ando, Y; Kamada, H; Masaki, T; Matsukawa, H; Okano, K; Oshima, M; Shibata, T; Suto, H; Suzuki, Y; Takahashi, S | 1 |
| Baba, S; Ishigami, K; Isoda, T; Kitamura, Y; Nakata, K; Nishie, A; Oda, Y; Shimomura, Y; Tabata, K; Yamada, Y | 1 |
| Abdelrahman, AM; Alva-Ruiz, R; Cleary, SP; Goenka, AH; Graham, RP; Grotz, TE; Haddock, MG; Halfdanarson, TR; Hallemeier, CL; Kendrick, ML; Leiting, JL; Ma, WW; McWilliams, RR; Merrell, KW; Nagorney, DM; Smoot, RL; Thiels, CA; Tran, NH; Truty, MJ; Warner, SG; Yonkus, JA | 1 |
| Buck, AK; Hartrampf, PE; Higuchi, T; Kosmala, A; Lindner, T; Michalski, K; Schirbel, A; Schlötelburg, W; Serfling, SE; Weich, A; Werner, RA | 1 |
| Abe, T; Baba, S; Fujimori, N; Fujita, N; Hayashi, M; Ideno, N; Ikenaga, N; Ishigami, K; Isoda, T; Murakami, M; Nakamura, M; Nakamura, S; Nakata, K; Oda, Y | 1 |
| Fukukura, Y; Hasegawa, K; Kageyama, S; Kameda, A; Marugami, N; Nakai, Y; Nakano, T; Nakaya, M; Sato, K; Sofue, K; Takahashi, M; Takeyama, N; Tanaka, M; Tashiro, Y; Watadani, T; Yoshimitsu, K | 1 |
| Ahn, E; Feng, D; Gu, B; Huang, Q; Jiang, C; Kim, J; Song, S; Yuan, Y | 1 |
| Bai, Y; Gao, J; Huang, X; Li, B; Lin, X; Miao, F; Rominger, A; Schwaiger, M; Shi, K; Zhu, H | 1 |
| Colbatzky, T; Giesel, FL; Glatting, FM; Gutjahr, E; Haberkorn, U; Hackert, T; Heger, U; Hielscher, T; Hoppner, J; Kratochwil, C; Lang, M; Liermann, J; Pausch, T; Röhrich, M; Spektor, AM; Sperling, L; van Genabith, L | 1 |
| Brennan, T; Chen, H; Goenka, AH; Herrmann, K; Jacobson, M; Karbhari, A; Kuo, PH; Mosessian, S; Patnam, NG; Simeone, DM; Trivedi, KH; Truty, MJ; Valla, F; Zan, E | 1 |
| Sauvanet, A; Wartski, M | 1 |
| Coriat, R; Palmieri, LJ | 1 |
| Arena, J; Bailey, EA; Chua, TC; Clarke, SJ; Gill, AJ; Hruby, G; Itchins, M; Jamieson, NB; Kneebone, A; Mittal, A; Nahm, CB; O'Connell, RL; Pavlakis, N; Samra, JS; Schembri, GP | 1 |
| Adler, SS; Brender, JR; Choudhuri, R; Choyke, PL; Devasahayam, N; Jagoda, EM; Kishimoto, S; Krishna, MC; Mitchell, JB; Oshima, N; Saito, K; Seki, T; Yamamoto, K | 1 |
| Abe, Y; Endo, Y; Hori, S; Ishii, R; Iwabuchi, Y; Jinzaki, M; Kitagawa, Y; Kitago, M; Masugi, Y; Matsusaka, Y; Nakahara, T; Okuda, S; Oshima, G; Shinoda, M; Takemura, R; Toyama, K; Yagi, H; Yokose, T | 1 |
| Abolmaali, N; Baumann, M; Blum, S; Distler, M; Folprecht, G; Grützmann, R; Jentsch, C; Polster, H; Saeger, HD; Troost, EGC; Weitz, J; Zimmermann, C; Zöphel, K | 1 |
| Byun, Y; Choi, Y; Han, Y; Jang, JY; Kang, J; Kim, H; Kwon, W; Moon, D | 1 |
| Ahopelto, K; Böckelman, C; Haglund, C; Hagström, J; Kauhanen, S; Saukkonen, K; Seppänen, H | 1 |
| Datta-Gupta, S; Garg, P; Kumar, R; Sharma, A; Sharma, R | 1 |
| Cheng, C; Li, M; Liu, Z; Peng, Y; Ren, S; Shen, J; Sun, G; Yang, X; Yang, Z; Zuo, C | 1 |
| Kim, K; Kim, SJ | 1 |
| Akita, H; Fujiwara, Y; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Moon, JH; Ohigashi, H; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Tomokuni, A; Yano, M; Yasui, M | 1 |
| Belfiori, G; Crippa, S; Falconi, M; Partelli, S; Pergolini, I; Pucci, A; Ruffo, G; Salgarello, M; Zamboni, G | 1 |
| Ariake, K; Fukase, K; Hayashi, H; Maeda, S; Masuda, K; Mizuma, M; Motoi, F; Naitoh, T; Ohtsuka, H; Shimomura, H; Takadate, T; Taki, Y; Tatewaki, Y; Terao, C; Unno, M | 1 |
| Dercle, L; Garg, I; Goenka, AH; Hough, DM; Wang, ZJ; Yeh, R | 1 |
| Beatty, GL; Chen, F; Gladney, WL; June, CH; Kulikovskaya, IM; Lacey, SF; Levine, BL; McGarvey, M; Melenhorst, JJ; Nazimuddin, F; Nelson, AM; O'Hara, MH; Plesa, G; Soulen, MC; Torigian, DA | 1 |
| Behr, S; Cinar, P; Collisson, EA; Consunji, MV; Gao, K; Ko, AH; Ohliger, MA; Tempero, MA; Wang, ZJ; Yeh, BM | 1 |
| Garg, I; Goenka, AH; Halfdanarson, TR; Johnson, GB; Panda, A; Truty, MJ | 1 |
| Kim, SK; Kim, YI; Lee, HY; Paeng, JC | 1 |
| Chen, RH; Chen, T; Liu, C; Liu, L; Long, J; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, YJ | 1 |
| Chang, DT; Chaudhry, M; Dholakia, AS; Griffith, ME; Hacker-Prietz, A; Herman, JM; Koong, AC; Laheru, DA; Leal, JP; Oteiza, KE; Pai, J; Pawlik, T; Raman, SP; Su, Z; Tryggestad, E; Wahl, RL; Wolfgang, CL | 1 |
| Ishibashi, M; Kage, M; Kaida, H; Kawahara, A; Kinoshita, H; Kitasato, Y; Okabe, Y; Okuda, K; Tanaka, H; Yasunaga, M | 1 |
| Cho, JY; Chung, KH; Han, HS; Hwang, DW; Hwang, JH; Lee, SH; Park, JK; Yoon, YS | 1 |
| Arisawa, T; Hosoki, T; Kawada, N; Shiroeda, H; Takami, M; Tomita, Y; Uehara, H | 1 |
| Brentnall, TA; Chen, R; Jeffrey, RB; Laeseke, PF; Willmann, JK | 1 |
| Choi, DW; Choi, JY; Choi, SH; Hyun, SH; Kim, BT; Kim, HS; Lee, JK; Lee, KH; Park, JO | 1 |
| Hwang, HK; Kang, CM; Lee, SH; Lee, WJ; Yun, M | 1 |
| Chiba, T; Haga, H; Hatano, E; Isoda, H; Kodama, Y; Kurita, A; Kuriyama, K; Minamiguchi, S; Nakamoto, Y; Sawai, Y; Togashi, K; Uemoto, S; Uza, N; Yoshimura, K | 1 |
| Feng, F; Huo, L; Jin, Z; Li, F; Liao, Q; Zhao, Y | 1 |
| Halbrook, CJ; Lyssiotis, CA | 1 |
| Baba, H; Chikamoto, A; Hashimoto, D; Inoue, R; Komohara, Y; Sakamaki, K; Shiraishi, S; Takamori, H; Yamanaka, T; Yamashita, Y; Yamashita, YI; Yoshida, N | 1 |
| Chong, JU; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Yun, M | 1 |
| Baiocchi, GL; Bertagna, F; Gheza, F; Giubbini, R; Giulini, SM; Pizzocaro, C; Portolani, N | 1 |
| Arizono, S; Doi, R; Haga, H; Hirokawa, Y; Isoda, H; Maetani, Y; Nakamoto, Y; Nitta, T; Shimada, K; Togashi, K; Yamashita, R | 1 |
| Chierichetti, F; Fassan, M; Parenti, AR; Pasquali, C; Pedrazzoli, S; Pizzi, S; Sperti, C | 1 |
| Reske, SN | 1 |
| Abasolo, I; Millán, O; Navarro, P; Pujal, J; Rabanal, RM; Real, FX; Serafin, A | 1 |
| Alkadhi, H; Donati, O; Fischer, MA; Hany, TF; Heinrich, S; Marincek, B; Scheffel, H; Soldini, D; Weber, A | 1 |
| Doi, R; Imai, H; Isoda, H; Iwanaga, Y; Kamo, N; Kanazawa, H; Kawaguchi, Y; Koizumi, M; Masui, T; Takada, Y; Uemoto, S | 1 |
| Doki, Y; Eguchi, H; Kim, T; Kitagawa, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tatsumi, M; Tomimaru, Y; Umeshita, K; Wakasa, K | 1 |
| Chaudhry, MA; Leach, SD; Serrano, OK | 1 |
| Fukuda, H; Hiraide, T; Kaneta, T; Nakamura, Y; Takahashi, S; Takanami, K; Takase, K; Tsuda, M | 1 |
| Bissoli, S; Chierichetti, F; Pasquali, C; Pedrazzoli, S; Sperti, C | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kim, MJ; Ku, BH; Lee, JK; Lee, KH; Lee, KT; Oh, CR | 1 |
| Asagi, A; Iguchi, H; Inoue, T; Nadano, S; Nasu, J; Nishimura, R; Ohta, K; Tanada, M; Teramoto, N; Yamamoto, K | 1 |
| Baiocchi, GL; Bertagna, F; Calanducci, D; Gheza, F; Giubbini, R; Giulini, SM; Grazioli, L; Portolani, N | 1 |
| Ishihara, T; Kurosawa, J; Mikata, R; Miyazaki, M; Otsuka, M; Saito, M; Sakai, Y; Sugiyama, H; Tada, M; Tawada, K; Tsuyuguchi, T; Uchida, Y; Uchiyama, K; Yokosuka, O | 1 |
| Baiocchi, GL; Bertagna, F; Giubbini, R; Treglia, G | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kitajima, K; Ku, Y; Matsumoto, I; Shinzeki, M; Shirakawa, S | 1 |
| Chierichetti, F; Decet, G; Liessi, G; Pasquali, C; Pedrazzoli, S; Sperti, C | 1 |
| Bosonnet, L; Connor, S; Evans, J; Garvey, CJ; Ghaneh, P; Hughes, M; Jayan, R; Lytras, D; Neoptolemos, JP; Sutton, R; Vinjamuri, S | 1 |
| Monden, T; Nishiyama, Y; Ohkawa, M; Sasakawa, Y; Satoh, K; Tsutsui, K; Yamamoto, Y; Yokoe, K | 1 |
| Chung, YF; Goh, BK; Ng, DC; Selvarajan, S; Soo, KC | 1 |
| Bissoli, S; Chierichetti, F; Frison, L; Liessi, G; Pasquali, C; Pedrazzoli, S; Sperti, C | 1 |
8 review(s) available for fluorodeoxyglucose f18 and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Care Planning; Patient Selection; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2019 |
Diagnostic Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Characterization of Intraductal Papillary Mucinous Neoplasms: An Updated Systematic Review and Meta-analysis.
Topics: Adenocarcinoma, Mucinous; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Fluorodeoxyglucose F18; Humans; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2021 |
The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Pancreatic Neoplasms; Patient Care Planning; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
Molecular radionuclide imaging of pancreatic neoplasms.
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Forecasting; Genes, Neoplasm; Humans; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2019 |
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cellular Reprogramming; Fluorodeoxyglucose F18; Glucose; Glutamine; Humans; Metformin; Pancreatic Neoplasms; Positron-Emission Tomography; Tumor Microenvironment | 2017 |
[PET and PET-CT of malignant tumors of the exocrine pancreas].
Topics: Adenocarcinoma; Carcinoma, Acinar Cell; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Disease Progression; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
The role of PET scanning in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Endosonography; Fluorodeoxyglucose F18; Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature.
Topics: Adenocarcinoma, Mucinous; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
6 trial(s) available for fluorodeoxyglucose f18 and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
Topics: Adenocarcinoma; Adult; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Fibroblasts; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Topics: Aged; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Female; Fluorodeoxyglucose F18; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Male; Mesothelin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Antigen, T-Cell; RNA, Messenger; Survival Rate; T-Lymphocytes; Transplantation, Autologous | 2018 |
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Blood Glucose; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Induction Chemotherapy; Liver; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Confidence Intervals; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals | 2012 |
Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole-Body Counting | 2005 |
51 other study(ies) available for fluorodeoxyglucose f18 and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Early Detection of Cancer; Fluorodeoxyglucose F18; Integrin alphaVbeta3; Mice; Oligopeptides; Pancreatic Neoplasms; Positron-Emission Tomography; Tissue Distribution | 2022 |
Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
Topics: CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2022 |
Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Glucose; Humans; Necrosis; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2022 |
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Digestive System Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
Topics: CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2023 |
Intraductal oncocytic papillary neoplasm of the pancreas: clinical and radiological features compared to those of intraductal papillary mucinous neoplasm.
Topics: CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Cysts; Fluorodeoxyglucose F18; Humans; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Preoperative prediction of microvascular invasion and perineural invasion in pancreatic ductal adenocarcinoma with
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
Prediction of synchronous distant metastasis of primary pancreatic ductal adenocarcinoma using the radiomics features derived from
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Nomograms; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2023 |
Comparison of early and late
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cholestasis; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Quinolines; Retrospective Studies; Tomography, X-Ray Computed | 2023 |
Topics: Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2019 |
Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Disease-Free Survival; Drug Therapy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Pancreatic Neoplasms; Positron-Emission Tomography | 2020 |
Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Electron Spin Resonance Spectroscopy; Fluorodeoxyglucose F18; Glucose; Glycolysis; Heterografts; Humans; Mice; Molecular Imaging; Oxygen; Pancreatic Neoplasms; Partial Pressure; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2020 |
Usefulness of
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Burden | 2020 |
Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2022 |
TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CT.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Transketolase | 2021 |
Role of dual-point 18F-FDG-PET/CT in the diagnosis of pancreatic adenocarcinoma, in patients with and without concomitant chronic pancreatitis: Comparison with CECT and EUS.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Male; Pancreatic Neoplasms; Pancreatitis, Chronic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Radiomics model of dual-time 2-[
Topics: Autoimmune Pancreatitis; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Tumor Burden | 2017 |
SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Analysis | 2018 |
18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Aged, 80 and over; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Period; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2018 |
Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
Topics: Aged; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Tumor Burden | 2018 |
Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Postoperative Period; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; ErbB Receptors; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Single-Blind Method; Survival Analysis; Tomography, X-Ray Computed | 2014 |
Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic ductal adenocarcinoma patients with diabetes.
Topics: Aged; Carcinoma, Pancreatic Ductal; Diabetes Complications; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2015 |
Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.
Topics: Adenocarcinoma; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Contrast Media; Cost-Benefit Analysis; Diagnostic Imaging; DNA Methylation; Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; MicroRNAs; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Biological Transport; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tumor Burden | 2016 |
Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.
Topics: Aged; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2016 |
Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Aorta; Bile Duct Neoplasms; Carcinoma; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Common Bile Duct Neoplasms; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2016 |
Intraductal Papillary Mucinous Neoplasm of the Pancreas With High Malignant Potential on FDG PET/MRI.
Topics: Bile Duct Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2017 |
Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.
Topics: Aged; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2017 |
Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results.
Topics: Adenocarcinoma, Mucinous; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
F-18 fluorodeoxyglucose uptake in a solid pseudopapillary tumor of the pancreas mimicking malignancy.
Topics: Adenocarcinoma, Papillary; Adolescent; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Pancreatic Cyst; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours.
Topics: Animals; Carcinoma, Acinar Cell; Carcinoma, Pancreatic Ductal; Elongin; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Genes, myc; Glucose Transport Proteins, Facilitative; Hexokinase; Male; Mice; Mice, Transgenic; Positron-Emission Tomography; RNA, Messenger; Transcription Factors | 2009 |
Intraductal oncocytic papillary neoplasm of the pancreas: a radio-pathological case study.
Topics: Aged; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Ultrasonography | 2010 |
Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Japan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2010 |
Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
Topics: Adenocarcinoma, Mucinous; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Pancreatic Ductal; Contrast Media; Female; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multidetector Computed Tomography; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2011 |
The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Pancreatic Ductal; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multidetector Computed Tomography; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Whole Body Imaging | 2013 |
Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
Topics: Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Diagnosis, Differential; Diagnostic Tests, Routine; Early Diagnosis; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Multidetector Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2013 |
F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cystadenocarcinoma; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pancreatic Cyst; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Spiral Computed | 2005 |
Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Chronic Disease; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Carcinoma, Pancreatic Ductal; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2007 |
18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |